Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose methotrexate-doxycycline interaction.

J J Tortajada-Ituren1, J P Ordovás-Baines, P Llopis-Salvia

  • 1Pharmacy Service, Dr. Peset University Hospital, Valencia, Spain. farmpese@san.gva.es

The Annals of Pharmacotherapy
|August 31, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

Biopharmaceutics & drug disposition·2015
Same author

Development and application to clinical practice of a validated HPLC method for the analysis of β-glucocerebrosidase in Gaucher disease.

Journal of pharmaceutical and biomedical analysis·2014
Same author

[Organization and management of nutritional care process in hospitalized patients: the model implemented in the "Hospital Universitario de La Ribera"].

Nutricion hospitalaria·2012
Same author

Animal model of undernutrition for the evaluation of drug pharmacokinetics.

Nutricion hospitalaria·2012
Same author

Assessing a therapeutic exchange protocol for second-generation antidepressants: clinical results.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2011
Same author

Management of returned anti-neoplastic treatments and their reuse in oncology patients.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2009
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Concurrent use of doxycycline with high-dose methotrexate (HD-MTX) can lead to dangerous drug interactions. This case highlights the potential for increased methotrexate plasma concentrations, toxicity, and significant impacts on patient quality of life and healthcare costs.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • High-dose methotrexate (HD-MTX) is a critical chemotherapy regimen for osteosarcoma.
  • Drug interactions can significantly alter treatment efficacy and safety profiles.
  • Monitoring methotrexate pharmacokinetics is essential for optimizing treatment and preventing toxicity.

Observation:

  • A patient receiving HD-MTX for osteosarcoma was concurrently treated with doxycycline for a palpebral abscess.
  • Pharmacokinetic monitoring revealed elevated methotrexate plasma concentrations and prolonged half-life during co-administration.
  • The patient experienced severe hematologic and gastrointestinal toxicity, requiring prolonged hospitalization and treatment delays.

Findings:

  • The co-administration of doxycycline with HD-MTX resulted in significant pharmacokinetic changes compared to previous cycles.

Related Experiment Videos

  • A statistically significant increase (p < 0.05) in methotrexate plasma concentrations and altered pharmacokinetic parameters was observed.
  • These changes led to severe clinical toxicity, impacting the patient's quality of life.

    • Implications:

    • The interaction between methotrexate and doxycycline necessitates careful consideration in clinical practice.
    • Healthcare providers should be aware of potential pharmacokinetic alterations and clinical repercussions.
    • Managing such interactions is crucial for patient well-being, treatment adherence, and controlling associated healthcare costs.